Endometrial Cancer Trials Face Scrutiny Over Unaddressed Chemotherapy Question
Four major clinical trials for dMMR endometrial cancer—RUBY, NRG-GY018, AtTEnd, and DUO-E—are under scrutiny for not including an immunotherapy-alone arm, which would determine the necessity of chemotherapy in combination treatments. These trials randomized patients to receive chemotherapy plus immunotherapy versus chemotherapy plus placebo, demonstrating significant benefits from adding immunotherapy. For instance, the RUBY trial showed a 72.8% 4-year overall survival rate with dostarlimab plus carboplatin-paclitaxel. However, none of these trials investigated whether carboplatin-paclitaxel contributes meaningfully to patient outcomes in this specific molecularly distinct population, leaving open the question of whether tens of thousands of patients receive unnecessary myelosuppressive chemotherapy. The common assumption in oncology is that combining cytotoxics with checkpoint inhibitors produces additive or synergistic benefits, but this assumption has not been stress-tested for dMMR tumors, which are bi...